精神分裂症女性乳腺癌风险及抗精神病药使用时长关联:韩国人群队列研究
该研究基于韩国国民健康信息数据库2007至2018年数据,匹配分析精神分裂症女性(n=224 612)、其他精神障碍女性(n=224 612)和一般人群女性(n=449 224)。结果显示精神分裂症女性乳腺癌风险较一般人群高1.26倍(95%CI 1.20-1.32),较其他精神障碍患者高1.17倍(95%CI 1.11-1.28),且抗精神病药使用≥1年者风险高于<6个月者。
要点
- 精神分裂症女性乳腺癌风险较一般人群高1.26倍(95%CI 1.20-1.32)。
- 精神分裂症女性乳腺癌风险较其他精神障碍女性高1.17倍(95%CI 1.11-1.28)。
- 抗精神病药使用≥1年者乳腺癌风险高于使用<6个月者。
核心结论
- 精神分裂症女性乳腺癌风险升高,长期使用抗精神病药与乳腺癌风险增加相关。
研究设计与样本
- 基于韩国国民健康信息数据库2007至2018年18至80岁女性医疗索赔数据的人群队列研究。
- 精神分裂症组为ICD-10编码F20或F25的女性(n=224 612),对照组为其他精神障碍女性(n=224 612)和一般人群女性(n=449 224),按索引日期和年龄1:1:2匹配。
- 采用Cox比例风险模型估计乳腺癌风险,调整保险费和医疗合并症。
- 在精神分裂症患者中采用landmark法估计抗精神病药使用时长与乳腺癌发病的关联。
主要发现
- 多变量Cox回归中,精神分裂症组乳腺癌风险率为一般人群的1.26倍(95%CI 1.20-1.32)。
- 与其他精神障碍患者组相比,风险比HR为1.17(95%CI 1.11-1.28)。
- 在精神分裂症女性中,抗精神病药使用≥1年者乳腺癌风险高于使用<6个月者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is a major global health issue, especially among women. Previous research has indicated a possible association between psychiatric conditions, particularly schizophrenia, and an increased risk of breast cancer. However, the specific risk of breast cancer in women with schizophrenia, compared with those with other psychiatric disorders and the general population, remains controversial and needs further clarification. AIMS: To estimate the risk of breast cancer among people with schizophrenia compared with people with other psychiatric disorders and people in the general population. METHOD: We utilised medical claims data of women aged 18 to 80 years in the Korean National Health Information Database from 2007 to 2018. Individuals with schizophrenia were defined as women with ICD-10 codes F20 or F25 (n = 224 612). The control groups were defined as women with other psychiatric disorders (n = 224 612) and women in the general Korean population (n = 449 224). Cases and controls were matched by index date and age, in a 1:1:2 ratio. We estimated the hazard of breast cancer using the Cox proportional hazards model, adjusting for insurance premiums and medical comorbidities. Among the people with schizophrenia, we used the landmark method to estimate the association between duration of antipsychotic medication use and the incidence of breast cancer. RESULTS: In multivariable Cox regression models, the hazard rate of breast cancer was 1.26 times higher in the people with schizophrenia than in the general population (95% CI: 1.20-1.32). In comparison with the psychiatric patient group, the hazard ratio was 1.17 (95% CI: 1.11-1.28). Among women with schizophrenia, the hazard of breast cancer was greater among those who took antipsychotic medications for 1 year or more compared with those who took antipsychotics for less than 6 months. CONCLUSIONS: Women with schizophrenia have an elevated risk of breast cancer, and long-term use of antipsychotics is associated with an increased risk of breast cancer.
引用
- Yang JS, Kang S, Kim K, et al. Breast cancer risk among women with schizophrenia and association with duration of antipsychotic use: population-based cohort study in South Korea. Br J Psychiatry. 2024. PMID: 39480277. doi:10.1192/bjp.2024.170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。